| Code | CSB-RA004954MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to cusatuzumab, targeting CD70, a type II transmembrane glycoprotein member of the tumor necrosis factor superfamily. CD70 serves as the ligand for CD27 and plays a critical role in T cell and B cell activation and differentiation. Under normal physiological conditions, CD70 expression is tightly regulated and limited to activated lymphocytes. However, aberrant CD70 expression is observed in various hematological malignancies, including acute myeloid leukemia (AML), non-Hodgkin lymphomas, and multiple myeloma, as well as in certain solid tumors such as renal cell carcinoma and glioblastoma, making it an attractive therapeutic target.
Cusatuzumab is a fully humanizedized IgG1 monoclonal antibody that binds to CD70 with high affinity, mediating antibody-dependent cellular cytotoxicity and direct tumor cell killing. This biosimilar antibody provides researchers with a valuable tool for investigating CD70 biology, exploring immune checkpoint mechanisms, and studying potential therapeutic interventions in CD70-expressing malignancies. It supports preclinical research in oncology and immunology, facilitating the development of novel treatment strategies.
There are currently no reviews for this product.